Cell and gene therapies introduce a different set of development questions: does the engineered product have the intended identity and phenotype, does it recognize the target, and does it perform the desired biological function? Boveevo supports early and translational CGT programmes with functional cell-based and molecular assays for CAR-T, CAR-NK and other gene-modified therapies. We connect potency and cytotoxicity with activation, persistence, phenotype, transgene expression and quantitative molecular measurements, creating a practical assay strategy that can evolve as a programme moves from discovery characterization toward more advanced analytical development. Where specialized or regulated capabilities are required, we can coordinate qualified partner laboratories.